Abstract
The purpose of this study was to assess the apoptotic -related gene expression of single-agent oxaliplatin in vitro. Growth inhibition studies were performed using the human cerebral cavernous malformation-1 colorectal adenocarcinoma cell line and mucosa-associated lymphoid tissue-nt-1 lymphoma cell line. At 50% inhibitory concentrations, oxaliplatin displayed suppressive effects toward Bcl-2 and the surviving expression in human cancer cell lines, whereas the expression of Fas/FasL was completely abolished in peripheral blood cells. Our data showed that oxaliplatin exerts potent antiapoptotic effects in human normal peripheral blood mononuclear cells at the suprapharmacologic concentration, warranting further investigations in the role of autoimmune adverse events while being used in numerous cycles for the treatment of malignancies.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
